Amarin

Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Retrieved on: 
Wednesday, April 24, 2024
American Heart, FDA, Patient, HealthyWomen, University, Stroke, Professional corporation, Risk, Woman, Food, CVD, Health, Death, Fenofibrate, History, Prescription, Science, CFR, Commissioner, Cardiovascular disease, Clinical trial, Associate, Amarin, Medical director, Pharmaceutical industry

“Despite the many safe, effective, and FDA-approved treatments available on the market with clinically proven reductions of CVD risk, patients are still being treated with fenofibrates off-label.

Key Points: 
  • “Despite the many safe, effective, and FDA-approved treatments available on the market with clinically proven reductions of CVD risk, patients are still being treated with fenofibrates off-label.
  • This results in patients taking a drug proven to have no clinical benefit to reduce CVD risk,” said Nabil Abadir, M.D., Chief Medical Officer at Amarin.
  • “This is a significant issue that is risking patient health and should be addressed quickly by the FDA.
  • The petition also urges the FDA Commissioner to further clarify the position the agency previously took by removing the statin co-administration from fenofibrate labeling.

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Retrieved on: 
Monday, April 15, 2024
Amarin, Conference, Professional corporation, Q&A

The conference call with management will follow the release of the Company’s first quarter 2024 financial results in the pre-market hours.

Key Points: 
  • The conference call with management will follow the release of the Company’s first quarter 2024 financial results in the pre-market hours.
  • Starting on April 15th at 8:00 am ET, all shareholders are encouraged to submit questions by visiting: https://app.saytechnologies.com/amarin-2024-q1 .
  • This Q&A platform will remain open until 48 hours prior to the start of the earnings call.
  • Conference Call and Webcast Information:
    Access to the live call:
    Dial in within the United States: 888-506-0062

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Retrieved on: 
Monday, March 25, 2024
MB, Amarin, REDUCE, CH.B, Risk, Patient, SVP, Research, American College, EPA, Abadir Umar ar-Rida, MACE, Professional corporation, IPE

DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.

Key Points: 
  • These data demonstrate the molecule’s impact in reducing patients’ residual cardiovascular event risk across these patient sub-groups regardless of their baseline Lp(a) or LDL-C levels.
  • Additionally, the meeting provides an opportunity to highlight further evidence regarding the potential mechanistic activity of EPA in reducing cardiovascular events in at-risk patients."
  • “This latest research reaffirms Amarin's commitment to advancing cardiovascular care and should help further advance the medical community’s understanding of the role, the value and the potential mechanism of action of VASCEPA/VAZKEPA to reduce cardiovascular events in at-risk patients globally,” concluded Abadir.
  • Featured Amarin-supported abstracts to be presented by international academic collaborators at ACC Scientific Sessions 2024 include:

Theratechnologies Appoints Jordan Zwick to its Board of Directors

Retrieved on: 
Friday, March 22, 2024
Amarin, Chair, Patient, Atlantic University, Bausch Health, Strategic planning, Salix Pharmaceuticals, Sale, Acquisition, University, TSX, Florida Atlantic University

“We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors,” said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies.

Key Points: 
  • “We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors,” said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies.
  • I look forward to collaborating with my board colleagues and the management team to drive shareholder value and make a profound impact on the patients we serve,” said Jordan Zwick.
  • Mr. Zwick has vast executive industry operational experience at companies such as Amarin, InflaRx, Salix Pharmaceuticals and Bausch Health.
  • With the appointment of Jordan Zwick, the Company’s Audit Committee will now comprise three independent members including Gerald Lacoste and Frank Holler as Chair.

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Retrieved on: 
Thursday, February 15, 2024
Professional corporation, Amarin, Q&A, Conference

ET.

Key Points: 
  • ET.
  • The call will include brief remarks on 2023 highlights followed by Q&A.
  • The conference call with management will follow the release of the Company’s fourth quarter and full year 2023 financial results in the pre-market hours.
  • Conference Call and Webcast Information:
    Access to the live call:
    Dial in within the United States: 888-506-0062

Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

Retrieved on: 
Monday, December 4, 2023
School, Business school, Business, CFO, Catalyst Pharmaceuticals, Amarin, Accounting, Professional corporation, Growth, State university system, Senior, Management

CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024. Mr. Kalb will report directly to the Company’s Chief Executive Officer and will serve as a member of the Company's executive leadership team. Mr. Kalb's distinguished career in finance spans over three decades in the pharmaceutical and financial services sector. He succeeds Ms. Alicia Grande, who will retire from the Company at the end of this year.

Key Points: 
  • Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer
    CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024.
  • Mr. Kalb will report directly to the Company’s Chief Executive Officer and will serve as a member of the Company's executive leadership team.
  • Before joining the Company, Mr. Kalb served as Chief Financial Officer at Impel Pharmaceuticals, Inc., and previously served as Executive Vice President and Chief Financial Officer of CinCor Pharma, Inc. Further, Mr. Kalb served as Senior Vice President and Chief Financial Officer of Amarin Corporation plc, where he contributed to its significant revenue growth, increased market capitalization, and successfully led multiple financing rounds of varying sizes and structures.
  • Additionally, we are pleased to announce that effective on January 1, 2024, Dr. Steven Miller will be promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen will be promoted to Executive Vice President, Chief Commercial Officer.

Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership

Retrieved on: 
Monday, December 4, 2023
Banking, Professional Services, Finance, Patient, Pershing Square Capital Management, Sarissa, Partnership, Professional corporation, Amarin

Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):

Key Points: 
  • Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
    Sarissa believes Amarin’s stock is significantly undervalued.
  • We hope that recent progress detailed below will cause the stock to begin to reflect the value we think it has.
  • We have never sold any shares of Amarin and have only increased our position since we made the investment.
  • We are pleased with the progress that Amarin has made to date and expect the value to be reflected in the stock price over time.

Amarin Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Research, SMC, Medicare, Prescription, Risk, Forecasting, CVRR, Telephone, Health technology assessment, GAAP, HTA, Commercial, Marketing, Healthcare Improvement Scotland, Professional corporation, Investment, Patient, Hypertriglyceridemia, National Medical Products Administration, Conference, Organization, IPE, Medicaid, NMPA, File, Socialist Alternative (England, Wales & Scotland), ASEAN, Rare-earth element, Management, Pharmaceutical industry, Health insurance, Video game, Cryptocurrency, Bank, Amarin

-- Company to Host Conference Call Today at 8:00 a.m. ET --

Key Points: 
  • ET --
    DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced financial results for the quarter ended September 30, 2023 and provided an update on company operations.
  • “As we focus on demonstrating results that will drive shareholder value, there are reasons to be optimistic about the future of Amarin,” said Patrick Holt, President & CEO of Amarin.
  • U.S. product net revenue was $62.4 million in the third quarter of 2023, a decline of $2.2 million versus the second quarter of 2023, a decrease of 3% sequentially.
  • The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations.

Lexicon Strengthens Management Team With Two New Executives

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, National Investor Relations Institute, Professional corporation, Bristol Myers Squibb, Melinta Therapeutics, Policy, AbbVie, Lexicon, Therapy, Ophthalmology, Actavis, Intercept, BS, Seton Hall University, Ozanimod, University, Amarin, Warner Chilcott, MBA, Ladenburg Thalmann, Alemtuzumab, Allergan, Business administration, Marketing, Wall Street, Watson Labs, Villalba v Merrill Lynch & Co Inc, Sclerosis, Heart failure, Intercept Pharmaceuticals, Pharmaceutical industry

THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.

Key Points: 
  • Mr. Cullen brings Lexicon more than 35 years of industry experience in market access and sales leadership.
  • Before joining Lexicon, Matt served as vice president, value, access and policy at Apellis Pharmaceuticals where he led the market access launch of rare disease drug EMPAVELI® (pegcetacoplan) and ophthalmology drug SYFOVRE® (pegcetacoplan injection).
  • His responsibilities included pricing and contracting, payer strategy and marketing, corporate and strategic account management, field reimbursement, trade and distribution, and training.
  • Prior to Apellis, Mr. Cullen led strategic payer marketing and access teams at Bristol-Myers Squibb for ELIQUIS® (apixaban) and ORENCIA® (abatacept).

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

Retrieved on: 
Tuesday, October 31, 2023
Pace University School of Law, Business development, Intellectual property, State University of New York at Oswego, Chief, Lehigh University, Bristol Myers Squibb, Mallinckrodt, Professional corporation, General counsel, Patent, Management, Amarin, Chemistry

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief Legal & Compliance Officer. He will join the Company on November 15.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief Legal & Compliance Officer.
  • Mr. Provoost, who most recently served as Vice President, General Counsel and Chief Compliance Officer at Tris Pharma, Inc., brings more than 20 years of corporate legal experience, having served most of his career in large and medium-sized pharmaceutical companies.
  • Mr. Provoost’s broad experience in the legal profession includes serving as Chief Compliance Officer and General Counsel, management of intellectual property, general transactions, litigation, and various business activities.
  • Throughout Jonathan’s career he has enjoyed positions of increasing managerial responsibility, and most recently, served as Vice President, General Counsel and Chief Compliance Officer at Tris Pharma, Inc.